Jordan Giancoli of Kerrisdale Capital: Long on Dongbu

HFA Padded
HFA Staff
Published on
Updated on

Jordan Giancoli of Kerrisdale Capital, InvestPitch presentation produced by sumzero and Institutional Investor on the long case for Dongbu Insurance Co., Ltd. (KRX:005830).

Also see: Joshua Kennedy of Sonian Capital Management: Long Ryohin

Dongbu Insurance

Investment Thesis

Dongbu Insurance Co., Ltd. (KRX:005830) Insurance is South Korea’s second-largest non-life insurer. The business has been profitable for twenty consecutive years and has compounded book value at an annualized rate of 16% since 2005. Dongbu has a trailing return on equity of roughly 17% and trades at just 1.2x Price/Book Value and 8.2x 2013E P/E. These valuation multiples are too cheap for a well-run insurer that has a long track record of growing book value in a conservative manner. Dongbu has a competitive advantage over its peers due to the lowest expense ratio in the industry. Dongbu also boasts KRW 18trn ($16.9bn) of investable assets (Dongbu’s ‘float’), a figure that would make many U.S. insurers envious. Even with a return on assets of just 2.5%, Dongbu’s massive float allows it to earn double-digit RoEs from its investment income alone.

Dongbu Insurance Co., Ltd. (KRX:005830) has three business lines: auto, long-term (healthcare), and general. The economics of the auto insurance business would be familiar to any U.S. investor except for one key difference: Korea has a fixed-price regime. Politicians will sometimes cut rates to score points with voters, as they did in April 2012, and this has a direct impact felt across the industry. Insurers will continue to write policies since auto insurance provides a hook to incent customers to buy other products, such as supplemental life and casualty insurance.

But regulators can only push so far. Dongbu Insurance Co., Ltd. (KRX:005830)’s weaker competitors have seen their risk-based capital ratios fall as a result, and it seems only a matter of time before regulators reverse course. Dongbu also markets supplemental healthcare products, which South Koreans use to complement their state-funded care. This business is generally break-even but provides Dongbu with much of its float volume. Lastly, Dongbu maintains a small property & casualty book with the property side of the book largely in run-off mode.

H/T Curry Goat

Jordan Giancoli of Kerrisdale Capital: Long on Dongbu

HFA Padded

The post above is drafted by the collaboration of the Hedge Fund Alpha Team.

Leave a Comment